Artificial Intelligence in Drug Discovery and Biotech; 2022 Recap and Key Trends
Biopharmaceutical Report I Issue26_February 2023 The advent of AI in drug discovery at a glance The current advent of artificial...
Artificial Intelligence in Drug Discovery and Biotech; 2022 Recap and Key Trends
Anlysis of Bio - Pharma in East Asia - Trends Report
Astellas/Medivation's Xtandi has questionable potential to displace bicalutamide
Spark's LCA2 gene therapy is likely to have greater benefit for younger patients
Biosimilar Reference Products Expected to Grow
Diabetic Neuropathy Patient Stratification, Chances Boosted
J&J may suffer over AbbVie,Amgen in renewed biologic USpayer contracts as Celltrion’sbiosimilar loom
Array/Novartis’ binimetinib expected to best chemotherapy in Phase III trial despite protocol change
The Unrealized Potential of Stem Cell Therapy
*Novartis’ LCZ696 for CHFdraws approval optimism aftermeeting difficult Phase IIIendpoints